Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects

• Status: Completed
• Trial end date: 2005-09-01

Summary

This study is not being conducted in the United States.

To investigate the relative efficacy of pimecrolimus cream 1% applied twice daily (b.i.d.) versus once daily (o.d.) in preventing the progression to disease "relapse".

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Pimecrolimus; Tacrolimus